Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.66 |
| ▸ | DRD4 | P21917 | 7/20 | 0.66 |
| ▸ | HTR2C | P28335 | 8/20 | 0.35 |
| ▸ | HTR2B | P41595 | 8/20 | 0.35 |
| ▸ | HTR2A | P28223 | 6/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7444710 | 0.94 | DRD2 (0.66) | DRD2DRD4HTR2CHTR2BHTR2A | |
| SCHEMBL7445533 | 0.79 | DRD4 (0.63) | DRD2DRD4HTR2CHTR2BHTR2A | |
| SCHEMBL7449107 | 0.69 | DRD4 (0.58) | DRD2DRD4HTR2CHTR2BHTR2A | |
| SCHEMBL7453514 | 0.61 | DRD4 (0.62) | DRD2DRD4HTR2CHTR2B | |
| SCHEMBL22542166 | 0.57 | CYP1A2 (0.62) | — | |
| Hydrochloric Acid SCHEMBL9343101 | 0.54 | HTR2C (0.51) | DRD2HTR2CHTR2BHTR2A | |
| SCHEMBL16174401 | 0.53 | CA1 (0.53) | — | |
| SCHEMBL16081205 | 0.53 | ALDH1A1 (0.54) | POLB | |
| SCHEMBL4511428 | 0.53 | CYP2D6 (0.45) | HTR2CPOLB | |
| SCHEMBL10187102 | 0.53 | L3MBTL1 (0.60) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020193364-A1 | 1-azatricyclic-4-benzylpiperazines | NEUROGEN CORPORATION (US) | 2002-12-19 | — | — | US | claimed |
| US-20020025956-A1 | 1-azatricyclic-4-benzylpiperazines | HODGETTS KEVIN (US) | 2002-02-28 | — | — | US | claimed |
| US-6294530-B1 | HETEROCYCLIC COMPOUNDS FOR NERVOUS SYSTEM DISORDERS | NEUROGEN CORPORATION | 2001-09-25 | — | — | US | claimed |
| US-20020193364-A1 | 1-azatricyclic-4-benzylpiperazines | NEUROGEN CORPORATION (US) | 2002-12-19 | — | — | US | disclosed |
| US-6403591-B1 | NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2002-06-11 | — | — | US | disclosed |
| US-20020025956-A1 | 1-azatricyclic-4-benzylpiperazines | HODGETTS KEVIN (US) | 2002-02-28 | — | — | US | disclosed |
| US-6294530-B1 | HETEROCYCLIC COMPOUNDS FOR NERVOUS SYSTEM DISORDERS | NEUROGEN CORPORATION | 2001-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025956-A1 | 1-azatricyclic-4-benzylpiperazines | GABRA5, GABRA1, GABBR1 | DRD2 40/4885DRD4 67/4885HTR2C 42/4885 |
| US-20020193364-A1 | 1-azatricyclic-4-benzylpiperazines | GABRA5, GABRA1, GABBR1 | DRD2 40/4885DRD4 67/4885HTR2C 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.